Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
Interventions
- DRUG: Olaparib + durvalumab + UV1
Sponsor
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]